ALKERMES | ALKS - Pre Tax Profit


ALKERMES reported $-61.93M in Pre-Tax Profit for its fiscal quarter ending in March of 2026.





Pre Tax Profit Change Date
AbbVie USD 7.61B 2.04B Jun/2026
Acadia Pharmaceuticals USD 46.47M 42.49M Jun/2026
ALKERMES USD -61.93M 122.3M Mar/2026
Amgen USD 2.08B 570M Mar/2026
Biogen USD 647.3M 269.6M Jun/2026
BioMarin Pharmaceutical USD 141.2M 168.36M Mar/2026
Bristol-Myers Squibb USD 4.99B 1.75B Jun/2026
Coherus Biosciences USD -46.35M 90.86M Dec/2025
Eli Lilly USD 8.85B 583.8M Mar/2026
Gilead Sciences USD -7.53B 10.11B Jun/2026
Heron Therapeutics USD -2.95M 14.54M Dec/2025
Ionis Pharmaceuticals USD -114M 21M Jun/2026
J&J USD 8.66B 839M Jun/2026
Merck USD -3.53B 6.95B Mar/2026
Minerva Neurosciences USD 22.51M 30.74M Sep/2024
Nektar Therapeutics USD -43.09M 8.39M Mar/2026
Neurocrine Biosciences USD 246.8M 7.4M Mar/2026
Otsuka Holdings JPY 130.23B 54.96B Mar/2026
Pfizer USD -653M 5.84B Jun/2026
Regeneron Pharmaceuticals USD 1.53B 696.6M Jun/2026
Vertex Pharmaceuticals USD 1.25B 78.1M Mar/2026